We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Rapid COVID-19 Variant Test Speeds SARS-CoV-2 Mutation Tracking From Weeks to Hours

By LabMedica International staff writers
Posted on 23 Sep 2021

Efforts by researchers to identify and track variants of the SARS-CoV-2 virus has led to the creation and future implementation of a new method to “fingerprint” all currently known COVID-19 mutations. More...

The method developed by researchers at the UW School of Medicine (Seattle, Wash., (USA) identifies the presence of dozens of mutations at once and requires only three ingredients: a dipstick, a common thermocycler instrument, and a processed test sample. Upon coming into contact with the sample, the dipstick records which variant is present by exposing a series of lines, or bands. Every known variant of interest and concern has a correlating band pattern, which the test administrator can match to the sample.

Currently the definitive method of tracking variants of the virus, including the delta variant, is done through genomic sequencing. The process is thorough but can take up to two weeks to collect a sufficiently large batch of samples and yield results. The new method provides high-resolution results much more quickly, with a single or a few samples in hand. A grant awarded through the National Institutes of Health is fueling the development of the test, which will also include a barcode component that can be scanned through a smartphone app. The app connects the user to a database of all variant fingerprints. Preprogrammed and battery-capable thermocyclers will also be made available for distribution with test materials.

The test is already available as a prototype in the form of a same-day to next-day service in the UW School of Medicine lab on a collaborative basis, while a wider distribution of the full kit for clinical epidemiologists and researchers could come by this winter. The method is also designed with a key ability: potentially tracking new variants as they emerge, according to the researchers.

“It's a rapid test. We can identify the variant within two hours of the sample being in hand,” said UW School of Medicine Microbiology Professor Evgeni Sokurenko. “With emergence of new variants, generally, what we see right now involves a new combination of the known mutations. So we will be able to detect with this test, [the] emergence of new combinations of mutations, meaning new variants.”

Related Links:

UW School of Medicine


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.